These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 2117107)

  • 1. Interleukin-2 therapy for human cancer.
    van Hoesel QG
    Lung; 1990; 168 Suppl():1069-74. PubMed ID: 2117107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An explanation of the variable clinical response to interleukin 2 and LAK cells.
    Parmiani G
    Immunol Today; 1990 Apr; 11(4):113-5. PubMed ID: 2187466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Interleukin 2: immunologic background and clinical use in tumor therapy].
    Dummer R; Welters H; Keilholz U; Tilgen W; Burg G
    Hautarzt; 1990 Feb; 41(2):53-5. PubMed ID: 2180854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of human leukocyte antigen-mismatched allogeneic lymphokine-activated killer cells and interleukin-2 in the adoptive immunotherapy of patients with malignancies.
    Kimoto Y
    Hum Cell; 1992 Sep; 5(3):226-35. PubMed ID: 1467321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer, cytokines, and cytotoxic cells: interleukin-2 in the immunotherapy of human neoplasms.
    Atzpodien J; Kirchner H
    Klin Wochenschr; 1990 Jan; 68(1):1-11. PubMed ID: 2407894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monoclonal antibody therapy of murine lymphoma: enhanced efficacy by concurrent administration of interleukin 2 or lymphokine-activated killer cells.
    Schultz KR; Klarnet JP; Peace DJ; Cheever MA; Badger CC; Bernstein ID; Greenberg PD
    Cancer Res; 1990 Sep; 50(17):5421-5. PubMed ID: 2386946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Adoptive immunotherapy in malignant tumors].
    Kiselevskiĭ MV
    Vestn Ross Akad Med Nauk; 2003; (1):40-4. PubMed ID: 12608084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adoptive immunotherapy of a rat glioma using lymphokine-activated killer cells and interleukin 2.
    Tzeng JJ; Barth RF; Clendenon NR; Gordon WA
    Cancer Res; 1990 Jul; 50(14):4338-43. PubMed ID: 2364388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adoptive immunotherapy of malignant diseases with IL-2-activated lymphocytes.
    Kimoto Y; Taguchi T
    Biken J; 1987 Jun; 30(2):29-38. PubMed ID: 3501954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin 2 and lymphokine-activated killer cell therapy: analysis of a bolus interleukin 2 and a continuous infusion interleukin 2 regimen.
    Clark JW; Smith JW; Steis RG; Urba WJ; Crum E; Miller R; McKnight J; Beman J; Stevenson HC; Creekmore S
    Cancer Res; 1990 Nov; 50(22):7343-50. PubMed ID: 2224862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adoptive immunotherapy using lymphokine-activated killer cells and recombinant interleukin-2 in preventing and treating spontaneous pulmonary metastases of syngeneic Dunning rat prostate tumor.
    Tjota A; Zhang YQ; Piedmonte MR; Lee CL
    J Urol; 1991 Jul; 146(1):177-83. PubMed ID: 2056587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adoptive immunotherapy of human cancer using low-dose recombinant interleukin 2 and lymphokine-activated killer cells.
    Schoof DD; Gramolini BA; Davidson DL; Massaro AF; Wilson RE; Eberlein TJ
    Cancer Res; 1988 Sep; 48(17):5007-10. PubMed ID: 3261630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The influence of anticancer agents at various stages to induce LAK cell on its cytotoxicity and cell yield. Examination in vitro].
    Baba M
    Nihon Ika Daigaku Zasshi; 1990 Dec; 57(6):531-40. PubMed ID: 2286645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Local administration of autologous lymphokine-activated killer cells and recombinant interleukin 2 to patients with malignant brain tumors.
    Yoshida S; Tanaka R; Takai N; Ono K
    Cancer Res; 1988 Sep; 48(17):5011-6. PubMed ID: 3261631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction by interleukin-7 of lymphokine-activated killer activity in lymphocytes from autologous and syngeneic marrow transplant recipients before and after systemic interleukin-2 therapy.
    Pavletic Z; Benyunes MC; Thompson JA; Lindgren CG; Massumoto C; Alderson MR; Buckner CD; Fefer A
    Exp Hematol; 1993 Sep; 21(10):1371-8. PubMed ID: 8359237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LAK cell therapy--clinical studies and future potential.
    Marshall GD; Schwartzberg LS; Tauer KW; Lee P; Holbert JM; West WH
    Prog Clin Biol Res; 1990; 337():555-8. PubMed ID: 2191342
    [No Abstract]   [Full Text] [Related]  

  • 17. Adoptive immunotherapy of human pancreatic cancer with lymphokine-activated killer cells and interleukin-2 in a nude mouse model.
    Marincola FM; Da Pozzo LF; Drucker BJ; Holder WD
    Surgery; 1990 Nov; 108(5):919-29. PubMed ID: 2237773
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of lymphokine-activated killer cells and interleukin-2 in treating metastatic renal cell carcinoma.
    Fujioka T; Nomura K; Hasegawa M; Ishikura K; Kubo T
    Br J Urol; 1994 Jan; 73(1):23-31. PubMed ID: 8298895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Adoptive immunotherapy with LAK cell and IL-2 against primary lung cancer].
    Kimura H; Yamaguchi Y
    Nihon Geka Gakkai Zasshi; 1989 Sep; 90(9):1459-62. PubMed ID: 2586439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regional adoptive immunotherapy with interleukin-2 and lymphokine-activated killer (LAK) cells for liver metastases.
    Keilholz U; Scheibenbogen C; Brado M; Georgi P; Maclachlan D; Brado B; Hunstein W
    Eur J Cancer; 1994; 30A(1):103-5. PubMed ID: 8142149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.